Skip to main content
Equibles

NIKI · Niki BioSolutions, Inc.

Track NIKI — free

Use NIKI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NIKI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.80 -0.28 (-13.47%)
Rebalance outlook locked
Market Cap
$6.49M
Shares
3.12M
Volume · Oct 20 22.32K Avg daily vol (3M) 159.12K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.03 Open$2.07 Day$1.90–2.14 52W close$2.03–16.20 Avg vol 30d33K Short int15K · 0.5% float · 1.0d Short vol10% DataJan 2020–Oct 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.5%
Latest settlement · 1.0 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −75%
below
Price vs 50-day avg −64%
below
RSI (14) 20
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −58%
trailing
6-month return −77%
trailing
YTD return −81%
this year
Relative strength −85%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow Distributing
-38% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.47% of float · ▲ +11.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
5 holders — mid 3-yr range
Squeeze score 31
low risk · 0–100
Fundamentals
Weak
Revenue growth −67%
Y/Y
EPS growth +76%
Y/Y
Free cash flow $-1.8M
Quant / Vol
risk profile
Very High
Volatility 97%
annualized · 1-yr
Max drawdown −87%
past year
ATR 24.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−75% Bearish
Price vs 50-day avg
−64% Bearish
RSI (14)
20 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow Distributing
-38% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.47% of float · ▲ +11.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
5 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $2 · 0% Range high $16
vs 200-day avg -75% vs 50-day avg -64%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NIKI
Niki BioSolutions, Inc.
this stock
$6.49M — -66.7% — 0.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +13.5% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +4.6% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $64.50B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
5
% held
0.3%
Net QoQ
-6.2K sh
Top holder
JANE STREET GROUP, LLC
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
14.6K
Days to cover
1.0d
Change
+1.5K sh
View
Short Volume
Short vol %
10%
As of
Oct 19, 2026
Short Total
View
Fails to Deliver
FTD shares
709
Value
$3.4K
As of
Sep 29, 2026
View
Off-Exchange
Off-exchange %
22.0%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$431.4K
Net income (FY)
$-1.4M
EPS diluted
$-1.90
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 13, 2026
This year
26

Niki BioSolutions appointed Thomas Freeburg Chief Financial Officer on October 9, 2026, effective September 1, 2026, for two years. He receives a $250,000 base salary, up to a 50% bonus and 50,000 options exercisable at $8.83 per share.

View

Performance

5D 20D 120D MTD YTD
NIKI -22.7% -57.9% -76.9% -58.6% -80.9%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY -21.5% -57.3% -84.9% -59.4% -93.6%
Key facts CIK 1734005 CUSIP 653942102 Visit website Investor relations